What Is Xilio Therapeutics, Inc. (XLO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Xilio Therapeutics, Inc.. Trading at $9.12 against an estimated intrinsic value of $17.19, 7 of 9 active models flag meaningful upside of +88.5% on average. The most optimistic model, Regime Cross, places fair value at $35.36 (+287.8%), while ML-RIV — the most conservative — estimates $4.58 (-49.8%). This +337.5% gap reflects genuine analytical uncertainty about Xilio Therapeutics, Inc.'s intrinsic worth.
What Do the Models Say About XLO?
9 of 13 models are currently active for XLO. Of these, 8 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates XLO's intrinsic value at $16.02, implying +75.6% upside from the current price. See which stocks rank higher →
How Does XLO Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, XLO ranks #160 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Xilio Therapeutics, Inc. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is XLO a Value Trap?
CirclFi's Value Trap algorithm assigns XLO a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Xilio Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Xilio Therapeutics, Inc.'s fundamental quality profile registers 5.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +337.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every XLO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across XLO's 9 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad